Acute Coronary Syndrome Therapy Flashcards

1
Q

Common causes of ACS (4)

A
  • Atherosclerotic plaque rupture or erosion
  • Superimposed platelet aggregation and thrombosis
  • Vasospasm and vasoconstriction
  • Subtotal or transient total occlusion of vessel
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What ACS patient has a high lilelihood of coronary thrombus occluding the infarct artery

A

STEMI patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

if no PCI has been performed within 2 hours what should be used

A

Thrombolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What type of agents are thrombolytic drugs

A

Serine proteases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What do thrombolytic agents do

A

Converts plasminogen to activated state Plasmin

This lyses clots by breaking down fibrin and fibrinogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the 2 types of Thrombolytic agents

A

Fibrin specific

Non-fibrin specific

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fibrin specific agenst

A

Alteplase
Reteplase
Tenecteplase
Catalyse conversion of plasminogen to plasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Non-fibrin specific agents

A

Streptokinase

Catalyse systemic fibrinolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Contraindication of using thrombolysis (7)

A

Risk of heavy bleeding:
• Prior intracranial haemorrhage
• Known structural cerebral vascular lesion
• Known malignant intracranial neoplasm
• Ischaemic stroke within 3 months
• Suspected aortic dissection
• Active bleeding or bleeding diathesis (excluding menses)
• Significant closed-head trauma or facial trauma within 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

If there is no evidence of STEMI what medication should be used (6)

A
  • Aspirin
  • Tigagrelor/Clopidogrel (anti-platelet/blood thinner)
  • Fondaparinux/LMW (low molecular weight) heparin (anti-coagulant agents)
  • Intravenous nitrate
  • Analgesia
  • Beta Blockers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What other medications can be used

A

Prasugrel
Giibiia inhibitors
Statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management to reduce risk from NSTEMI

A
  • PCI or CABG
  • Aspirin- potent inhibitor of thromboxane A2 production which stimulates aggregation and vasoconstriction
  • Clopidogrel, prasugrel, ticagrelor, ticlopidine or cilostazol
  • Heparin (LM)
  • Fondaparinux
  • Giib/iiia receptor blockers
  • Statins
  • B blockers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the mechanism of aspirin

A

Inhibits the production of thromboxane A2 which stimulates aggregation and vasoconstriction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When can aspirin be used daily (3)

A

Acute MI
Unstable angina
Secondary prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the mechanism of clopidogrel

A

Anti-platelet
Prodrug
Inhibits ADP receptor activated platelet aggregation of platelets and crosslinking of fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What receptor does Clopidogrel specifically inhibit

A

P2Y12 ADP which blocks the activation of the GP iib/iiia pathway

17
Q

What is the iib/iiia complex a receptor for

A

Fibrinogen
Fibronectin
Vin WF

18
Q

What must clopidogrel be always used with

A

Aspirin

19
Q

Why might someone have clopidogrel resistance

A

This drug is activated by CYP2C19 and 14% of the population have low levels of this enzyme

20
Q

What are the benefits of using Prasugrel over clopidogrel

A

Inhibits ADP-induced platelet aggregation more rapidly, more consistently

21
Q

Low molecular weight heparin 94)

A
  • Enoxaparin
  • Dalteparin
  • Tinzeparin
  • Fondaparinux
22
Q

What is GIIb/IIIa

A

Integrin complex found on platelets

23
Q

What is the role of GPIIb/IIIa

A

induces production of fibrinogen once activated by ADP and undergoes a conformational change

24
Q

What is the action of GPIIb/IIIa inhibitors

A

inhibits fibrinogen binding to the activated form of GPIIb/IIIa on tow adjacent platelets and blocking aggregation

25
Q

Anticoagulant drugs target

A

Factor Xa

Production of thrombin from prothrombin

26
Q

Antiplatelet drugs

A
  • Inhibit ADP activation of GPIIb/IIIa pathway (aspirin, clopidogrel, prasugrel)
  • Inhibition of ADP leads to an Inhibition of the activation of thromboxane
27
Q

When can beta blockers be used

A

Post MI

Secondary prevention

28
Q

Examples of B blockers

A

IV atenolol

IV metoprolol

29
Q

Mechanism of beta blockers

A

Competitively inhibit the myocardial effects of catecholamines and reduce oxygen consumption by reducing HR, BP and contractility

30
Q

Who would receive a beta blocker within 24 hours of admission

A

> 70 years
HR >110 bpm
Systolic pressure <120 mmHG